Scarica l'app Stockscreener
1.40
0.72%
0.01
Dopo l'orario di chiusura:
1.39
-0.01
-0.71%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.39
Aprire:
$1.35
Volume 24 ore:
159.15K
Relative Volume:
0.79
Capitalizzazione di mercato:
$35.76M
Reddito:
Utile/perdita netta:
$-8.09M
Rapporto P/E:
-3.2154
EPS:
-0.4354
Flusso di cassa netto:
$-7.37M
1 W Prestazione:
+1.45%
1M Prestazione:
-7.28%
6M Prestazione:
+7.69%
1 anno Prestazione:
-2.22%
Intervallo 1D:
$1.3301
$1.47
Intervallo di 1 settimana:
$1.30
$1.53
Portata 52W:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.40 | 35.76M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | Alliance Global Partners | Buy |
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
Form 424B5 NanoViricides Inc For: 21 October By Investing.com - Investing.com Nigeria
NanoViricides files prospectus for $2.375M common stock offering - scanx.trade
Form 424B5 NanoViricides Inc For: 21 October By Investing.com - Investing.com Canada
Form 424B5 NanoViricides Inc For: 21 October By Investing.com - Investing.com UK
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials - Yahoo Finance
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials - azcentral.com and The Arizona Republic
Price performance - Yahoo Finance Australia
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Press & Sun-Bulletin
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides - ACCESS Newswire
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives - The Tennessean
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives - IndyStar
Form DEF 14A NANOVIRICIDES For: 8 October By Investing.com - Investing.com Nigeria
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - Corsicana Daily Sun
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - FinancialContent
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - Yahoo Finance
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives - ACCESS Newswire
Ebola has killed 4,018 people in Congo. A trial is finding a tolerable dose for an oral drug. - Stock Titan
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
Book value per share of NanoViricides, Inc. – HAN:NV3P - TradingView
Cash flow from financing activities of NanoViricides, Inc. – HAN:NV3P - TradingView
NanoViricides, Inc. Balance Sheet – HAN:NV3P - TradingView
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - ACCESS Newswire
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - Yahoo! Finance Canada
NanoViricides, Inc. (NNVC) Files 10-K; NV-387 Enters Phase II Trials - TradingView
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - Yahoo Finance
NanoViricides: Fiscal Q4 Earnings Snapshot - Yahoo Finance
NanoViricides: Fiscal Q4 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Q4 Earnings Snapshot - KHOU
NANOVIRICIDES, INC. FY 2026: Revenue $0 EPS ($0.41) — 10-K Summary - TradingView
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides - ACCESS Newswire
An Ebola trial in Congo is dosing patients with a drug that dissolves in the mouth. - Stock Titan
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides - Yahoo Finance
NanoViricides, Inc. Auditor Raises 'Going Concern' Doubt - www.marketscreener.com
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides Inc. (NNVC) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides - ACCESS Newswire
NanoViricides, Inc. (NNVC) Starts Phase II Trial of NV-387 for Mpox - TradingView
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides - Yahoo Finance
Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides - Yahoo Finance
About 48% of confirmed Ebola cases in Congo have ended in death. NanoViricides' oral trial is set to start next week. - Stock Titan
Cash flow from financing activities of NanoViricides, Inc. – HAM:NV3P - TradingView
Operating cash flow per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Return on equity % of NanoViricides, Inc. – HAM:NV3P - TradingView
Gross margin % of NanoViricides, Inc. – HAM:NV3P - tradingview.com
CapEx per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Total debt per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Basic earnings per share (basic EPS) of NanoViricides, Inc. – HAM:NV3P - TradingView
NanoViricides Registers Phase II Ebola Trial for Oral Antiviral NV-387 in DRC - citybuzz.co
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.09%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):